India's CDMOs & CROs Set to Advance Growth Amid Positive Market Momentum

The expansion of Indian CDMOs and CROs will accelerate because of the generally positive environment. As per Mordor Intelligence, the contract manufacturing sector is expected to double within the next five years, reaching $44.63 billion. Government estimates suggest that the contract research market is expected to experience a 10.75% CAGR (compounded annual growth rate), reaching $2.5 billion by 2030.

The Indian pharmaceutical sector is unconcerned about the potential advantages for Chinese biotech companies after the removal of the Biosecure Act, which intended to blacklist them, from an important US defense budget Bill.

Domestic pharmaceutical companies are wagering on the Act, which is poised to blacklist five Chinese biotech companies from federally-funded research and contracts. "The defence Bill does not replace the Biosecure Act." The two Acts operate separately from one another. "We expect no negative effects on the domestic pharmaceutical industry," stated Viranchi Shah, national president of the Indian Drugs Manufacturers Association.

Domestic pharmaceutical companies are counting on the Act, which remains set to blacklist five Chinese biotech companies from research and contracts funded by the federal government. “The defence Bill does not supersede the Biosecure Act.” Both Acts operate independently from one another. "We do not expect any negative effects on the domestic pharmaceutical sector," stated Viranchi Shah, national president of the Indian Drugs Manufacturers Association.